Early access
Sign in
Taking people in United KingdomNo phase

Imaging plaque activity in people with peripheral arterial disease

Uses body scans to study artery plaque in people with peripheral arterial disease.

Key facts

Who runs it
University of Edinburgh
Where
Edinburgh, United KingdomSee the site
Trial code
Registry title
Symptomatic and Systemic Atherosclerotic Plaque Activity in Patients With Peripheral Arterial Disease Using Novel Imaging
Status
Recruiting
People taking part
100 people, planned
Started
31 Jul 2025
Expected to end
Jul 2029
Type of study
Observational
Treatments tested
  • Whole body [68Ga]DOTATATE PET-CT
  • Whole body [18F]GP1 PET-CT
  • Whole body [18F]NaF PET-CT
  • Whole body CT angiogram
Record updated
18 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with peripheral arterial disease that causes symptoms. It uses special whole body scans to study plaque in the arteries.

Age
Over 18 years.
Sex
Men and women can join.
Disease stage
Peripheral artery disease with symptoms. This means one of: leg pain when walking with ankle/arm blood pressure ratio <0.90 or artery narrowing >50% plus another condition (disease in >1 vascular bed, diabetes, heart failure, or chronic kidney disease with eGFR < 60 mL/min/1.73 m2); pain at rest, tissue death or gangrene of the limb; a past leg artery bypass or opening procedure; or a past leg or foot amputation for artery disease.
Earlier treatment
People cannot join if they had a leg artery opening procedure less than 6 weeks ago. People who need colchicine long term for another reason cannot join.

Main reasons for not taking part

  • Cannot take colchicine or iodine contrast dye
  • Kidney failure (glomerular filtration rate <30 mL/min/1.73 m2), cirrhosis or severe liver disease
  • Pregnant or breast-feeding, or not using reliable birth control
  • Current or planned long term use of cyclosporine, verapamil, HIV protease inhibitors, azole antifungals, or macrolide antibiotics (apart from azithromycin)
  • Life expectancy <1 year, or active diarrhoea

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Male or female aged > 18 years
  • Symptomatic atherosclerotic peripheral artery disease; Intermittent claudication; with ankle/arm blood pressure ratio <0.90 or artery stenosis >50% in addition to at least one of the following; >1 vascular bed affected by atherosclerosis; Diabetes; Heart failure; Chronic kidney disease (eGFR < 60 mL/min/1.73 m2); Rest pain or necrosis of limb or gangrene of limb; Revascularization defined as limb bypass surgery or endovascular revascularization procedures (irrespective of the specific device used), including percutaneous transluminal angioplasty/stent of iliac or infra-inguinal arteries or extra-anatomical bypass surgery; Leg or foot amputation for arterial vascular indications
  • Ability to give written or verbal informed consent

Who cannot take part

  • Recent lower limb revascularisation for symptomatic disease (<6 weeks)
  • Renal failure (glomerular filtration rate <30 mL/min/1.73 m2)
  • Cirrhosis or severe chronic liver disease
  • Current or planned long term use of cyclosporine, verapamil, HIV protease inhibitors, azole antifungals, or macrolide antibiotics (apart from azithromycin)
  • Contraindication to colchicine or iodinated contrast
  • Long term requirement for colchicine for another clinical indication
  • Active diarrhoea
  • Women who are pregnant or breast-feeding
  • Women of child-bearing potential not protected by reliable contraception or is planning conception during the study
  • Patients deemed unlikely to return for follow up
  • Life expectancy <1 year
  • Inability or unwilling to give informed consent

Where in United Kingdom

  • Royal Infirmary of EdinburghEdinburgh, United KingdomContact: Allison C Winarski, MBChB MRSC(Ed)Taking people

About the trial

What the trial wants to find out

The goal of this observational study is to characterise the relationships between inflammation, microcalcification and thrombus activity in atherosclerotic plaques in peripheral and systemic vascular territories in patients with symptomatic peripheral arterial disease.

The group in the trial

  • Patients with symptomatic peripheral arterial disease

    Treatment: Whole body [68Ga]DOTATATE PET-CT, Whole body [18F]GP1 PET-CT, Whole body [18F]NaF PET-CT, and Whole body CT angiogram

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Symptomatic and Systemic Atherosclerotic Plaque Activity in Patients With Peripheral Arterial Disease Using Novel Imaging
Plain-language title
Imaging plaque activity in people with peripheral arterial diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
18 September 2026